Recombination-activating gene 1 (Rag1)-deficient mice with severe combined immunodeficiency treated with lentiviral gene therapy demonstrate autoimmune Omenn-like syndrome

Journal of Allergy and Clinical Immunology

Volumn 133, Issue 4, 2014, Pages 1116-1123

  Van Til, Niek P ^a   Sarwari, Roya ^a   Visser, Trudi P ^a   Hauer, Julia ^b,c   Lagresle Peyrou, Chantal ^b   Van Der Velden, Guus ^a   Malshetty, Vidyasagar ^d   Cortes, Patricia ^d   Jollet, Arnaud ^e   Danos, Olivier ^e   Cassani, Barbara ^f,g   Zhang, Fang ^h   Thrasher, Adrian J ^h   Fontana, Elena ⁱ   Poliani, Pietro L ⁱ   Cavazzana, Marina ^b,e   Verstegen, Monique M A ^a   Villa, Anna ^f,j   Wagemaker, Gerard ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSERM   (France)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e HÔPITAL NECKER ENFANTS MALADES   (France)

^f CNR   (Italy)

^g HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF BRESCIA   (Italy)

^j SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

more..

Author keywords

autoimmune reactions; lentiviral gene therapy; Severe combined immunodeficiency

Indexed keywords

B CELL ACTIVATING FACTOR; CD11B ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CD8 ANTIGEN; DOUBLE STRANDED DNA ANTIBODY; HERMES ANTIGEN; IMMUNOGLOBULIN D ANTIBODY; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LENTIVIRUS VECTOR; MESSENGER RNA; RAG1 PROTEIN; RAG2 PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4 CD8 RATIO; CHIMERA; CONTROLLED STUDY; DRUG SAFETY; GENE DOSAGE; HEMATOPOIETIC STEM CELL; HUMORAL IMMUNITY; MALE; MOUSE; NONHUMAN; OMENN SYNDROME; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SEVERE COMBINED IMMUNODEFICIENCY; SPLEEN FOCUS FORMING VIRUS; T LYMPHOCYTE ACTIVATION; VIRAL GENE THERAPY;

AUTOIMMUNE REACTIONS; LENTIVIRAL GENE THERAPY; SEVERE COMBINED IMMUNODEFICIENCY;

ANIMALS; AUTOIMMUNITY; BONE MARROW CELLS; DISEASE MODELS, ANIMAL; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOPHENOTYPING; LENTIVIRUS; MALE; MICE; MICE, KNOCKOUT; PHENOTYPE; SEVERE COMBINED IMMUNODEFICIENCY; SPLEEN; T-LYMPHOCYTES; THYMUS GLAND; TRANSDUCTION, GENETIC; TRANSPLANTATION CHIMERA;

EID: 84897389322     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2013.10.009     Document Type: Article

References (41)

1. S. Tonegawa Somatic generation of antibody diversity Nature 302 1983 575 581
2. V. Marrella, V. Maina, and A. Villa Omenn syndrome does not live by V(D)J recombination alone Curr Opin Allergy Clin Immunol 11 2011 525 531
3. M.D. Railey, Y. Lokhnygina, and R.H. Buckley Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis J Pediatr 155 2009 834 840.e1
4. R.H. Buckley, S.E. Schiff, R.I. Schiff, L. Markert, L.W. Williams, and J.L. Roberts et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency N Engl J Med 340 1999 508 516
5. M. Cavazzana-Calvo, A. Fischer, S. Hacein-Bey-Abina, and A. Aiuti Gene therapy for primary immunodeficiencies: part 1 Curr Opin Immunol 24 2012 580 584
6. J.C. van der Loo, W.P. Swaney, E. Grassman, A. Terwilliger, T. Higashimoto, and A. Schambach et al. Critical variables affecting clinical-grade production of the self-inactivating gamma-retroviral vector for the treatment of X-linked severe combined immunodeficiency Gene Ther 19 2012 872 876
7. N. Cartier, S. Hacein-Bey-Abina, C.C. Bartholomae, G. Veres, M. Schmidt, and I. Kutschera et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy Science 326 2009 818 823
8. M. Cavazzana-Calvo, E. Payen, O. Negre, G. Wang, K. Hehir, and F. Fusil et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia Nature 467 2010 318 322
9. A. Aiuti, L. Biasco, S. Scaramuzza, F. Ferrua, M.P. Cicalese, and C. Baricordi et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome Science 341 2013 1233151
10. A. Biffi, E. Montini, L. Lorioli, M. Cesani, F. Fumagalli, and T. Plati et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy Science 341 2013 1233158
11. T. Dull, R. Zufferey, M. Kelly, R.J. Mandel, M. Nguyen, and D. Trono et al. A third-generation lentivirus vector with a conditional packaging system J Virol 72 1998 8463 8471
12. R. Zufferey, T. Dull, R.J. Mandel, A. Bukovsky, D. Quiroz, and L. Naldini et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery J Virol 72 1998 9873 9880
13. D. Cesana, J. Sgualdino, L. Rudilosso, S. Merella, L. Naldini, and E. Montini Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations J Clin Invest 122 2012 1667 1676
14. C. Lagresle-Peyrou, F. Yates, M. Malassis-Seris, C. Hue, E. Morillon, and A. Garrigue et al. Long-term immune reconstitution in RAG-1-deficient mice treated by retroviral gene therapy: a balance between efficiency and toxicity Blood 107 2006 63 72
15. C. Lagresle-Peyrou, F. Benjelloun, C. Hue, I. Andre-Schmutz, D. Bonhomme, and M. Forveille et al. Restoration of human B-cell differentiation into NOD-SCID mice engrafted with gene-corrected CD34+ cells isolated from Artemis or RAG1-deficient patients Mol Ther 16 2008 396 403
16. K. Pike-Overzet, M. Rodijk, Y.Y. Ng, M.R. Baert, C. Lagresle-Peyrou, and A. Schambach et al. Correction of murine Rag1 deficiency by self-inactivating lentiviral vector-mediated gene transfer Leukemia 25 2011 1471 1483
17. P. Mombaerts, J. Iacomini, R.S. Johnson, K. Herrup, S. Tonegawa, and V.E. Papaioannou RAG-1-deficient mice have no mature B and T lymphocytes Cell 68 1992 869 877
18. N.P. van Til, H. de Boer, N. Mashamba, A. Wabik, M. Huston, and T.P. Visser et al. Correction of murine Rag2 severe combined immunodeficiency by lentiviral gene therapy using a codon-optimized RAG2 therapeutic transgene Mol Ther 20 2012 1968 1980
19. M.W. Huston, N.P. van Til, T.P. Visser, S. Arshad, M.H. Brugman, and C. Cattoglio et al. Correction of murine X-linked SCID by lentiviral gene therapy using a codon-optimized IL2RG gene and minimal pretransplant conditioning Mol Ther 19 2011 1867 1877
20. N.P. van Til, D.M. Markusic, R. van der Rijt, C. Kunne, J.K. Hiralall, and H. Vreeling et al. Kupffer cells and not liver sinusoidal endothelial cells prevent lentiviral transduction of hepatocytes Mol Ther 11 2005 26 34
21. N.P. van Til, M. Stok, F.S. Aerts Kaya, M.C. de Waard, E. Farahbakhshian, and T.P. Visser et al. Lentiviral gene therapy of murine hematopoietic stem cells ameliorates the Pompe disease phenotype Blood 115 2010 5329 5337
22. A. Villa, C. Sobacchi, L.D. Notarangelo, F. Bozzi, M. Abinun, and T.G. Abrahamsen et al. V(D)J recombination defects in lymphocytes due to RAG mutations: severe immunodeficiency with a spectrum of clinical presentations Blood 97 2001 81 88
23. W. Giblin, M. Chatterji, G. Westfield, T. Masud, B. Theisen, and H.L. Cheng et al. Leaky severe combined immunodeficiency and aberrant DNA rearrangements due to a hypomorphic RAG1 mutation Blood 113 2009 2965 2975
24. J.E. Walter, F. Rucci, L. Patrizi, M. Recher, S. Regenass, and T. Paganini et al. Expansion of immunoglobulin-secreting cells and defects in B cell tolerance in Rag-dependent immunodeficiency J Exp Med 207 2010 1541 1554
25. V. Marrella, P.L. Poliani, A. Casati, F. Rucci, L. Frascoli, and M.L. Gougeon et al. A hypomorphic R229Q Rag2 mouse mutant recapitulates human Omenn syndrome J Clin Invest 117 2007 1260 1269
26. M.E. Morgan, J.H. van Bilsen, A.M. Bakker, B. Heemskerk, M.W. Schilham, and F.C. Hartgers et al. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans Hum Immunol 66 2005 13 20
27. J. Chou, R. Hanna-Wakim, I. Tirosh, J. Kane, D. Fraulino, and Y.N. Lee et al. A novel homogenous mutation in recombination activating gene 2 in 2 relatives with different clinical phenotypes: Omenn syndrome and hyper-IgM syndrome J Allergy Clin Immunol 130 2012 1414 1416
28. C. Kimchi-Sarfaty, J.M. Oh, I.W. Kim, Z.E. Sauna, A.M. Calcagno, and S.V. Ambudkar et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity Science 315 2007 525 528
29. W. Yu, H. Nagaoka, M. Jankovic, Z. Misulovin, H. Suh, and A. Rolink et al. Continued RAG expression in late stages of B cell development and no apparent re-induction after immunization Nature 400 1999 682 687
30. L.Y. Hsu, J. Lauring, H.E. Liang, S. Greenbaum, D. Cado, and Y. Zhuang et al. A conserved transcriptional enhancer regulates RAG gene expression in developing B cells Immunity 19 2003 105 117
31. W. Yu, Z. Misulovin, H. Suh, R.R. Hardy, M. Jankovic, and N. Yannoutsos et al. Coordinate regulation of RAG1 and RAG2 by cell type-specific DNA elements 5' of RAG2 Science 285 1999 1080 1084
32. N. Yannoutsos, V. Barreto, Z. Misulovin, A. Gazumyan, W. Yu, and N. Rajewsky et al. A cis element in the recombination activating gene locus regulates gene expression by counteracting a distant silencer Nat Immunol 5 2004 443 450
33. B.D. Sather, B.Y. Ryu, B.V. Stirling, M. Garibov, H.M. Kerns, and S. Humblet-Baron et al. Development of B-lineage predominant lentiviral vectors for use in genetic therapies for B cell disorders Mol Ther 19 2011 515 525
34. H.M. Kerns, B.Y. Ryu, B.V. Stirling, B.D. Sather, A. Astrakhan, and S. Humblet-Baron et al. B cell-specific lentiviral gene therapy leads to sustained B-cell functional recovery in a murine model of X-linked agammaglobulinemia Blood 115 2010 2146 2155
35. J. Wayne, H. Suh, Z. Misulovin, K.A. Sokol, K. Inaba, and M.C. Nussenzweig A regulatory role for recombinase activating genes, RAG-1 and RAG-2, in T cell development Immunity 1 1994 95 107
36. J. Wayne, H. Suh, K.A. Sokol, H.T. Petrie, M. Witmer-Pack, and S. Edelhoff et al. TCR selection and allelic exclusion in RAG transgenic mice that exhibit abnormal T cell localization in lymph nodes and lymphatics J Immunol 153 1994 5491 5502
37. V. Barreto, R. Marques, and J. Demengeot Early death and severe lymphopenia caused by ubiquitous expression of the Rag1 and Rag2 genes in mice Eur J Immunol 31 2001 3763 3772
38. A. Lombardo, P. Genovese, C.M. Beausejour, S. Colleoni, Y.L. Lee, and K.A. Kim et al. Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery Nat Biotechnol 25 2007 1298 1306
39. C. Mussolino, and T. Cathomen TALE nucleases: tailored genome engineering made easy Curr Opin Biotechnol 23 2012 644 650
40. H. Jacobs, D. Vandeputte, L. Tolkamp, E. de Vries, J. Borst, and A. Berns CD3 components at the surface of pro-T cells can mediate pre-T cell development in vivo Eur J Immunol 24 1994 934 939
41. V. Marrella, P.L. Poliani, E. Fontana, A. Casati, V. Maina, and B. Cassani et al. Anti-CD3ε mAb improves thymic architecture and prevents autoimmune manifestations in a mouse model of Omenn syndrome: therapeutic implications Blood 120 2012 1005 1014